Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of fibroblast growth factor-21 mature peptide in preparation of hepatic fibrosis treatment drugs

A technology of fibroblasts and growth factors, which is applied in the field of preparation of drugs for the treatment of liver fibrosis, can solve the problems of not treating liver fibrosis, and achieve the effect of inhibiting liver fibrosis

Inactive Publication Date: 2016-02-03
JIANGSU KANIONREAL BIOMEDICAL TECH CO LTD
View PDF1 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, there is no ideal drug for the treatment of liver fibrosis, as the famous hepatologist Hans Popper said: "Whoever can prevent or slow down the occurrence of liver fibrosis will cure most chronic liver diseases"

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fibroblast growth factor-21 mature peptide in preparation of hepatic fibrosis treatment drugs
  • Application of fibroblast growth factor-21 mature peptide in preparation of hepatic fibrosis treatment drugs
  • Application of fibroblast growth factor-21 mature peptide in preparation of hepatic fibrosis treatment drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Embodiment 1, the preparation of FGF-21 mature peptide

[0051] 1. Construction of recombinant plasmids

[0052] 1. Extract total RNA from isolated human liver.

[0053] 2. Using M-MLV reverse transcriptase to reverse transcribe the total RNA obtained in step 1 into cDNA.

[0054] 3. Using the cDNA obtained in step 2 as a template, using a primer pair composed of P1 and P2, and using rTaq enzyme, perform PCR amplification to obtain a PCR amplification product. After sequencing, the part between the restriction sites of BsaI and BamHI of the PCR amplification product is shown in sequence 2 of the sequence listing.

[0055] P1 (underlined BsaI recognition site): 5'-G GGTCTC TAGGTCACCCCCATCCCTGACTCCAGT-3';

[0056] P2 (underlined BamHI recognition site): 5'-CGC GGATCC TCAGGAAGCGTAGCTGGGGCTTCGG-3.

[0057] PCR amplification program: 95°C pre-denaturation for 5 minutes; 95°C for 30s, 56°C for 30s, 72°C for 45s, 25 cycles; 72°C for 10 minutes.

[0058] 4. The PCR amp...

Embodiment 2

[0078] Example 2. The therapeutic effect of FGF-21 mature peptide on liver fibrosis.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses application of a fibroblast growth factor-21 mature peptide in preparation of hepatic fibrosis treatment and / or prevention drugs. The invention also discloses a medicine for treating and / or preventing hepatic fibrosis, and the active ingredient of the medicine refers to the fibroblast growth factor-21 mature peptide. The fibroblast growth factor-21 mature peptide can effectively inhibit hepatic fibrosis, can serve as a medicine for treating and / or preventing hepatic fibrosis and has significant values for treating and / or preventing hepatic fibrosis.

Description

technical field [0001] The present invention relates to a new application of fibroblast growth factor-21 mature peptide, that is, the application of fibroblast growth factor-21 mature peptide in the preparation of liver fibrosis treatment medicine. Background technique [0002] Liver fibrosis is a pathological change caused by chronic liver damage caused by various reasons. It is characterized by excessive and abnormal deposition of extracellular matrix components (ECM) in the liver, thereby affecting liver function. It is a common pathological reaction of chronic liver damage. Eventually it will lead to cirrhosis, portal hypertension, liver failure and hepatocellular carcinoma. [0003] There are many causes of hepatic fibrosis, such as hepatitis B virus infection, fatty liver, long-term drinking and drugs, etc., which continuously damage the liver for a long time, which will lead to the formation of hepatic fibrosis. Among the causes of liver fibrosis, there are more than...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/18A61P1/16
Inventor 李德山徐鹏飞任桂萍
Owner JIANGSU KANIONREAL BIOMEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com